☆ 4.4 Article

COVID-19: vaccine's progress

MICROBIAL BIOTECHNOLOGY (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Lorena Sanchez-Felipe et al.

Summary: The candidate vaccine YF-S0, utilizing the YF17D vaccine as a vector to express noncleavable prefusion form of the SARS-CoV-2 spike antigen, showed excellent safety, immunogenicity, and efficacy in animal models. It induced high levels of neutralizing antibodies, provided protective immunity against SARS-CoV-2, and prevented infection in hamsters and macaques. A single dose was able to confer protection from lung disease in most vaccinated hamsters within 10 days, highlighting the potential of YF-S0 as a potent SARS-CoV-2 vaccine candidate.

NATURE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T. Widge et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Jing-Hui Tian et al.

Summary: The study reports the development of a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, showing immunogenicity in mice and protection in baboons with Matrix-M adjuvanted vaccine, supporting ongoing phase 1/2 clinical evaluation of NVX-CoV2373 with Matrix-M (NCT04368988).

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond et al.

Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

News Item Multidisciplinary Sciences

NOVAVAX OFFERS FIRST EVIDENCE THAT COVID VACCINES PROTECT PEOPLE AGAINST VARIANTS

Ewen Callaway et al.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike

Mijia Lu et al.

Summary: Using a measles virus vaccine strain as the backbone, researchers developed a series of recombinant attenuated vaccine candidates expressing various forms of the SARS-CoV-2 spike protein. Among these candidates, rMeV expressing stabilized prefusion S protein showed the highest potency in inducing neutralizing antibodies and provided complete protection against SARS-CoV-2 in animal models. This supports further development of rMeV-preS as a highly effective vaccine candidate against SARS-CoV-2.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Multidisciplinary Sciences

One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection

Ruikang Liu et al.

Summary: Research on modified vaccinia virus Ankara (MVA) expressing the S protein of SARS-CoV-2 showed promising results in inducing antibodies and CD8+ T cells, protecting transgenic mice from lethal infection, preventing nasal infection, reducing cytokine expression, and effectively terminating virus replication in vaccinated animals.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques

Pragya D. Yadav et al.

Summary: This study demonstrates the protective efficacy and immunogenicity of the inactivated SARS-CoV-2 vaccine BBV152 in rhesus macaques, indicating that the vaccine candidate is in clinical development.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques

Hyon-Xhi Tan et al.

Summary: The study compared the immunogenicity of spike proteins (S) and receptor binding domain (RBD) in SARS-CoV-2 vaccines in mice and macaques, finding that S was highly immunogenic in mice while RBD was comparatively poor. Both S and RBD vaccines were similarly immunogenic in macaques, inducing serological neutralising activity exceeding convalescent human levels.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Biology

Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

Nick K. Jones et al.

Summary: Research shows that there is a fourfold reduction in asymptomatic infection among healthcare workers post-vaccination with the first dose of the BNT162b2 vaccine. This indicates that a single dose of the vaccine can provide short-term protection against asymptomatic SARS-CoV-2 infection, reducing virus transmission and the burden of COVID-19 disease.

ELIFE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

COVID-19: emergence and mutational diversification of SARS-CoV-2

Harald Brussow

Summary: The origin of the SARS-CoV-2 virus is still uncertain, but a viral zoonosis from bats is the most likely hypothesis. Through intensive virological and epidemiological research, combined with massive sequencing efforts, insights into viral evolution mechanisms have been gained, impacting public health measures to contain the virus.

MICROBIAL BIOTECHNOLOGY (2021)

添加到收藏夹

Article Cell Biology

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Ahmed O. Hassan et al.

Summary: The study demonstrates the immunogenicity and protective efficacy of an intranasally administered vaccine in non-human primates, showing that it induces neutralizing antibodies and T cell responses, effectively limiting or preventing infection of SARS-CoV-2 in the respiratory tract.

CELL REPORTS MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Alexander A. Cohen et al.

Summary: The study developed nanoparticles displaying the receptor binding domain (RBD) of SARS-CoV-2 and other animal coronaviruses, which induced cross-reactive antibody responses in mice. Immunization with mosaic RBD nanoparticles resulted in superior neutralization of heterologous viruses, providing a potential strategy for simultaneous protection against multiple coronaviruses.

SCIENCE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

Ahmed O. Hassan et al.

CELL (2020)

添加到收藏夹

Article Multidisciplinary Sciences

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Jingyun Yang et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Ching-Lin Hsieh et al.

SCIENCE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru et al.

SCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

Liqiang Feng et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

添加到收藏夹

News Item Multidisciplinary Sciences

ARAB NATIONS FIRST TO APPROVE CHINESE COVID VACCINE

David Cyranoski

NATURE (2020)

添加到收藏夹

News Item Multidisciplinary Sciences

OXFORD COVID-VACCINE PAPER HIGHLIGHTS LINGERING UNKNOWNS ABOUT RESULTS

Heidi Ledford

NATURE (2020)

添加到收藏夹

News Item Multidisciplinary Sciences

OXFORD COVID VACCINE RESULTS PUZZLE SCIENTISTS Preliminary data suggest that the immunization was more effective when given in a lower dose

Ewen Callaway

NATURE (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccination - An Ounce (Actually, Much Less) of Prevention

Eric J. Rubin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

News Item Multidisciplinary Sciences

COVID-19 Amid the cheering, some vaccines face questions

Jon Cohen

SCIENCE (2020)

添加到收藏夹

Editorial Material Infectious Diseases

Inactivated COVID-19 vaccines to make a global impact

Patrick L. Iversen et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Alexandra C. Walls et al.

CELL (2020)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.